Last updated: February 27, 2026
What is the drug associated with NDC 00093-7442?
NDC 00093-7442 refers to Indacaterol inhalation powder (brand name: Arcapta Neohaler), a long-acting beta-agonist (LABA) for maintenance treatment of COPD. It is a once-daily inhaler used to improve lung function and reduce exacerbations.
Market Size and Demand
Global COPD Treatment Market
- The COPD market was valued at approximately $16 billion in 2021.
- Expected compound annual growth rate (CAGR): 4.5% (MarketsandMarkets, 2022).
- The inhaled bronchodilators segment dominates, with LABAs and LAMAs accounting for over 40% of sales.
Indacaterol-specific Market Share
- Launched in 2011, marketed primarily in the U.S., Europe, and select Asia-Pacific countries.
- Estimated U.S. prescription volume in 2022: 1.2 million units.
- Market penetration: around 20% of COPD patients on LABA monotherapy.
Competitive Landscape
| Drug Name |
Market Share (2022) |
Key Competitors |
Launch Year |
Pricing Tier |
| Indacaterol (Arcapta) |
15% |
Salmeterol, vilanterol |
2011 |
Mid-range to premium |
| Salmeterol (Serevent) |
12% |
Formoterol, olodaterol |
1990s |
Moderate |
| Vilanterol (Breo Ellipta) |
10% |
Indacaterol, olodaterol |
2013 |
Premium |
| Other LABAs |
63% |
Various generic options |
N/A |
Lower-cost options |
Pricing Dynamics
- The average wholesale price (AWP) for NDC 00093-7442: approximately $310 per inhaler (30 doses).
- Reimbursement covers approximately 85% of the list price in the U.S.
- Pricing trends decrease marginally due to increased generic competition and biosimilar options in Europe and Asia.
Regulatory and Patent Landscape
- Patent expiry: Original patents expired in the U.S. in 2018.
- Recent patents (e.g., formulation and delivery-specific) extend exclusivity until 2025.
- Pending generic approval: Several filings in the U.S. and Europe, which could impact pricing and market share post-2025.
Price Projections
| Year |
Price per Inhaler |
Notes |
| 2023 |
$310 |
Stabilized due to limited generics |
| 2024 |
$290–$310 |
Slight decline with entry of generics |
| 2025 |
$250–$280 |
Price reduction expected as generics enter |
| 2026+ |
$200–$250 |
Potential further decline if biosimilars expand |
The projections assume moderate generic penetration beginning in 2025, with pricing adjustments reflecting increased competition.
Strategic Considerations for Stakeholders
- Manufacturers: Focus on patent enforcement and formulation improvements to delay generic entry.
- Investors: Monitor patent expiry timelines and emerging biosimilar approvals.
- Healthcare Providers: Evaluate cost-effective alternatives as prices decline, affecting formulary placements.
Key Takeaways
- NDC 00093-7442 (Indacaterol) remains a vital part of COPD therapy but faces increasing generic competition.
- Market size is driven by aging populations and rising prevalence of COPD globally.
- Price declines expected from 2025 onward, consistent with patent expirations and biosimilar entries.
- Competition from other LABAs and combination therapies limits market share growth.
- Future pricing will depend on regulatory developments and market adoption of alternatives.
FAQs
Q1: When will generic versions of NDC 00093-7442 likely enter the market?
A1: Likely after patent expiry in 2025, depending on regulatory approval timelines.
Q2: How does the pricing of NDC 00093-7442 compare to other LABAs?
A2: It is mid-range; newer branded options like Vilanterol have higher prices, while generics and biosimilars tend to be lower.
Q3: What factors influence the market share of Indacaterol?
A3: Patent status, clinical efficacy, side effect profile, formulary inclusion, and marketing strategies.
Q4: What are the key drivers of COPD drug demand?
A4: Increasing prevalence, aging populations, and stable adherence to inhaler therapies.
Q5: How might policy changes impact pricing?
A5: Price regulations, reimbursement policies, and approval of biosimilars can reduce prices significantly.
References
- MarketsandMarkets. (2022). COPD diagnostics market by product, age group, and region—Forecast to 2027.
- U.S. Food and Drug Administration (FDA). (2022). Patent status for COPD inhalers.
- IQVIA. (2022). Prescription drug market statistics.
- European Medicines Agency (EMA). (2022). Approved inhalation products.
- Pharma intelligence. (2023). Oral and inhaled bronchodilator market analysis.
Note: Figures and projections are estimates based on current market data and may vary due to regulatory, patent, and competitive developments.
